Researchers demonstrated that selectively blocking peripheral cannabinoid receptors outside the brain improves memory, synaptic plasticity, and gut barrier integrity in fragile X syndrome mouse models. Tthe study shows that a one-week treatment restores beneficial gut bacteria and reverses hippocampal cognitive deficits without triggering central nervous system side effects.
Fragile X syndrome is the most common single-gene cause of inherited intellectual disability and autism spectrum disorder. Alongside cognitive impairment, memory deficits, hyperactivity, and autistic behaviors, individuals living with the condition frequently experience chronic gastrointestinal dysfunction, highlighting the intricate biological link between gut health and neurodevelopment. Despite decades of research, no targeted pharmacological therapies currently exist to treat the cognitive symptoms of fragile X syndrome.
Now, a study led by the Cognition Biology Research Group at Pompeu Fabra University (UPF) in Barcelona and published in Translational Psychiatry reveals that selectively targeting cannabinoid receptors outside the brain can simultaneously heal the gut microenvironment and rescue cognitive function.
Led by principal investigator Dr. Andrés Ozaita alongside co-first authors Lucía de los Reyes Ramírez and Araceli Bergadà-Martínez, the research demonstrates that just one week of peripheral endocannabinoid inhibition reverses synaptic alterations in the hippocampus and restores intestinal barrier integrity in fragile X mouse models.
Source: Neuroscience News — Read the full article on the original site ↗
